Emmaus Life Sciences Expresses Concerns Over Inaccuracies in Draft Report Issued by ICER (Institute for Clinical and Economic Review) Jan 27, 2020 8:00am EST
Emmaus Life Sciences Announces a New Adherence Program for Its Sickle Cell Disease Patients Jan 06, 2020 8:00am EST
Emmaus Life Sciences Announces First Purchase Order from its Partnership with taiba Healthcare Dec 31, 2019 4:01pm EST
Emmaus Life Sciences Announces Update of its Partnership with taiba Healthcare to Expand Patient Access for Sickle Cell Disease Treatment in the Middle East and North Africa (MENA) Region Dec 23, 2019 4:01pm EST
Emmaus Life Sciences Reports Preliminary Gross Sales for the Three Months Ended September 30, 2019 Oct 11, 2019 8:00am EDT
Emmaus Life Sciences Granted Patent in India for use of Pharmaceutical-grade L-glutamine in Treating Diverticulosis Oct 09, 2019 7:30am EDT
Emmaus Life Sciences Announces its Common Stock to Begin Trading on OTCQB September 26 Sep 26, 2019 8:00am EDT
Emmaus Life Sciences Reinforces Positive Outcomes of Endari ® Clinical Trials, Including Efficacy Findings That Led to FDA Approval Sep 24, 2019 7:00am EDT
